A bipartisan group of U.S. lawmakers is calling for an investigation into American biopharmaceutical companies conducting clinical trials in China, particularly in Xinjiang, where allegations of genocide against Uyghurs have been made. They raised concerns about potential intellectual property theft and the ethical implications of trials possibly involving coerced participation of Uyghurs. The lawmakers highlighted collaborations with hospitals affiliated with the Chinese military, asserting that such partnerships could jeopardize U.S. national security and lead to unreliable clinical trial data. The letter, directed to the FDA, emphasizes the need for scrutiny over hundreds of trials conducted over the past decade and seeks answers by October 1. Both Republican and Democratic leaders are united in their call for accountability in these practices. Beijing has denied any allegations of abuse or coercion in these trials.